CSF3 and non-small cell lung carcinoma: To minimize neutropenia and infection related to chemotherapy-induced immunosuppression, risk of hospitalization, and risk of related nosocomial SARS-CoV-2 acquisition, the use of G-CSF could be considered a priori in patients treated with platinum-based chemotherapy in the neoadjuvant and adjuvant setting and in patients with metastatic NSCLC if the risk of neutropenia is above 10% [12].